{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"43"}],"units":"Participants"}],"description":"Number of patients that discontinue study drugs due to treatment related toxicity; percentage will be summarized.","groups":[{"description":"Stage 1 - Dose Level 1 participants:\n\n* 3 mg MLN0128 daily\n* \\+ 10 mg/kg bevacizumab every 2 weeks","id":"OG000","title":"Dose Level 1 - 3 mg MLN0128 Daily"},{"description":"Stage 1 - Dose Level 2 participants:\n\n* 4 mg MLN0128 daily\n* \\+ 10 mg/kg bevacizumab every 2 weeks","id":"OG001","title":"Dose Level 2 - 4 mg MLN0128 Daily"},{"description":"Inclusive of both Stage 1 - Dose Level 3 participants and Stage 2 participants treated at the MTD:\n\n* 5 mg MLN0128 daily\n* \\+ 10 mg/kg bevacizumab every 2 weeks","id":"OG002","title":"Dose Level 3 - 5 mg MLN0128 Daily"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Number of Patients That Discontinue Study Drugs Due to Treatment Related Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}